Emerging immunotherapy and strategies directly targeting B cells for the treatment of diffuse large B-cell lymphoma

Immunotherapy

Volumn 7, Issue 1, 2015, Pages 37-46

  Witkowska, Magdalena ^a   Smolewski, Piotr ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

BCR signaling; diffuse large B cell lymphoma; DLBCL; immunochemotherapy; immunomodulatory drugs; lymphoid neoplasms; monoclonal antibody; treatment; tyrosine kinase inhibitors

Indexed keywords

CD20 ANTIBODY; IMMUNOMODULATING AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; VASCULOTROPIN ANTIBODY; ANTINEOPLASTIC AGENT; RITUXIMAB;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; COMPLEMENT DEPENDENT CYTOTOXICITY; HUMAN; INTRACELLULAR SIGNALING; LARGE CELL LYMPHOMA; MONOTHERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW; SIGNAL TRANSDUCTION; TUMOR REGRESSION; ANIMAL; APOPTOSIS; DRUG DELIVERY SYSTEM; DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOMA, LARGE B-CELL, DIFFUSE; PATHOLOGY; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOTHERAPY; LYMPHOMA, LARGE B-CELL, DIFFUSE; SIGNAL TRANSDUCTION;

EID: 84920944207     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.14.93     Document Type: Review

References (75)

1. Fisher RI, Miller TP, O'Connor OA. Diffuse aggressive lymphoma. Hematology Am. Soc. Hematol. Educ. Program 2004, 221-236 (2004).
2. Fisher SG, Fisher RI. The emerging concept of antigen-driven lymphomas: epidemiology and treatment implications. Curr. Opin. Oncol. 18(5), 417-424 (2006).
3. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403(6769), 503-511 (2000).
4. Lenz G, Wright G, Dave SS et al. Stromal gene signatures in large-B-cell lymphomas. N. Engl. J. Med. 359(22), 2313-2323 (2008).
5. Rosenwald A, Wright G, Chan WC et al. Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 346(25), 1937-1947 (2002).
6. Lam LT, Wright G, Davis RE et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood 111(7), 3701-3713 (2008).
7. Wright G, Tan B, Rosenwald A et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc. Natl Acad. Sci. USA 100(17), 9991-9996 (2003).
8. Savage KJ, Johnson NA, Ben-Neriah S et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 114(17), 3533-3537 (2009).
9. Johnson NA, Savage KJ, Ludkovski O et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 114(11), 2273-2279 (2009).
10. Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin lymphoma. N. Engl. J. Med. 328(14), 1002-1006 (1993).
11. Cartron G, Watier H, Golay J et al. From the bench to the bedside: ways to improve rituximab efficacy. Blood 104(9), 2635-2642 (2004).
12. Sehn LH, Donaldson J, Chhanabhai M et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J. Clin. Oncol. 23(22), 5027-5033 (2005).
13. Sehn LH, Berry B, Chhanabhai M et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109(5), 1857-1861 (2007).
14. Gisselbrecht C, Glass B, Mounier N et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J. Clin. Oncol. 28(27), 4184-4190 (2010).
15. Beers SA, Chan CH, James S et al. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood 112(10), 4170-4177 (2008).
16. Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 103(7), 2738-2743 (2004).
17. Hagenbeek A, Gadeberg O, Johnson P et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a Phase 1/2 trial. Blood 111(12), 5486-5495 (2008).
18. Cheson BD. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J. Clin. Oncol. 28(21), 3525-3530 (2010).
19. Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C et al. Ofatumumab demonstrates activity against rituximab-sensitive and-resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma. Br. J. Haematol. 156(4), 490-498 (2012).
20. Matasar MJ, Czuczman MS, Rodriguez MA et al. Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. Blood 122(4), 499-506 (2013).
21. Ivanov A, Beers SA, Walshe CA et al. Homotypic adhesion and lysosome-mediated cell death evoked by anti-CD20 (Tositumomab) and HLA DR monoclonal antibodies. J. Clin. Invest. 119(8), 2143-2159 (2009).
22. Davies AJ. A review of tositumomab and I (131) tositumomab radioimmunotherapy for the treatment of follicular lymphoma. Expert Opin. Biol. Ther. 5(4), 577-588 (2005).
23. Srinivasan A, Mukherji SK. Tositumomab and iodine I 131 tositumomab (Bexaar). Am. J. Neuroradiol. 32(4), 637-638 (2011).
24. Kaminski MS, Estes J, Zasadny KR et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 96(4), 1259-1266 (2009).
25. Ivanov A, Beers SA, Walshe CA et al. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J. Clin. Invest. 119(8), 2143-2159 (2009).
26. Alduaij W, Ivanov A, Honeychurch J et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood 117(17), 4519-4529 (2011).
27. Salles GA, Morschhauser F, Cartron G et al. A Phase I/II study of RO5072759 (GA101) in patients with relapsed/refractory CD20+ malignant disease. ASH Annu. Meeting Abstracts 112(11), 234 (2008).
28. Salles G, Morschhauser F, Lamy T et al. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood 119(22), 5126-5132 (2012).
29. Morschhauser FA, Cartron G, Thieblemont C et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the Phase II GAUGUIN study. J. Clin. Oncol. 31(23), 2912-2919 (2013).
30. Walker JA, Smith KG. CD22: an inhibitory enigma. Immunology 123(3), 314-325 (2008).
31. Polson AG, Williams M, Gray AM et al. Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma. Leukemia 24(9), 1566-1573 (2010).
32. Advani A, Coiffier B, Czuczman MS et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a Phase I study. J. Clin. Oncol. 28(12), 2085-2093 (2010).
33. Kreitman RJ, Stetler-Stevenson M et al. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J. Clin. Oncol. 27(18), 2983-2990 (2009).
34. Polson AG, Williams M, Gray AM et al. Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma. Leukemia 24(9), 1566-1573 (2010)
35. Micallef IN, Maurer MJ, Wiseman GA et al. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. Blood 118(15), 4053-4061 (2011).
36. Ling SC, Lau EK, Al-Shabeeb A et al. Response of myeloma to proteasome inhibitor bortezomib is correlated with unfolded protein response regulator XBP-1. Haematologica 97(1), 64-72 (2012).
37. Fuchs O. Targeting of NF-kappaB signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma. Cardiovasc. Hematol. Disord. Drug Targets 13(1), 16-34 (2013).
38. Furman RR, Martin P, Ruan J et al. Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. Cancer 116(23), 5432-5439 (2010).
39. Dimopoulos M, Spencer A, Attal M et al. Multiple Myeloma (010) Study Investigators Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N. Engl. J. Med. 357(21), 2123-2132 (2007).
40. List A, Dewald G, Bennett J et al. Myelodysplastic Syndrome-003 Study Investigators Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N. Engl. J. Med. 355(14), 1456-1465 (2006).
41. Martiniani R, Di Loreto V, Di Sano C, Lombardo A et al. Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma. Adv. Hematol. 2012, 842945 (2012).
42. McDaniel JM, Pinilla-Ibarz J, Epling-Burnette PK. Molecular action of lenalidomide in lymphocytes and hematologic malignancies. Adv. Hematol. 2012, 513702 (2012).
43. Zhu YX, Braggio E, Shi CX et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 118(18), 4771-4779 (2011).
44. Zhu D, Corral LG, Fleming YW et al. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol. Immunother. 57, 1849-1859 (2008).
45. Zhang LH, Kosek J, Wang M et al. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression. Br. J. Haematol. 160(4), 487-502 (2013).
46. Wiernik PH, Lossos IS, Tuscano JM et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J. Clin. Oncol. 26(30), 4952-4957 (2008).
47. Witzig TE, Vose JM, Zinzani PL et al. Durable responses after lenalidomide oral monotherapy in patients with relapsed or refractory (R/R) aggressive non-hodgkin's lymphoma (a-NHL): results from an international Phase 2 study (CC-5013-NHL-003). Blood 114, 1676 (2009).
48. Lenz G, Staudt LM. Aggressive lymphomas. N. Engl. J. Med. 362(15), 1417-1429 (2010).
49. Geahlen RL. Syk and pTyr'd: signaling through the B cell antigen receptor. Biochim. Biophys. Acta 1793(7), 1115-1127 (2009).
50. Davis RE, Brown KD, Siebenlist U et al. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J. Exp. Med. 194, 1861-1874 (2001).
51. Compagno M, Lim WK, Grunn A et al. Mutations of multiple genes cause deregulation of NF-kB in diffuse large B-cell lymphoma. Nature 459(7247), 717-21 (2009).
52. Friedberg JW, Sharman J, Sweetenham J et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115(13), 2578-2585 (2010).
53. McAdoo SP, Tam FW. Fostamatinib disodium. Drugs Future 36(4), 273 (2011).
54. Friedberg JW, Sharman J, Sweetenham J et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115(13), 2578-2585 (2010).
55. LoPiccolo J, Blumenthal GM, Bernstein WB et al. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist. Updat. 11(1-2), 32-50 (2008).
56. Uddin S, Hussain AR, Siraj AK et al. Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 12(13), 4178-4186 (2006).
57. Lannutti BJ, Meadows SA, Herman SE et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 117(2), 591-594 (2011).
58. Furman RR, Byrd JC, Flinn IW et al. Interim results from a Phase I study of CAL-101, a selective oral inhibitor of phosphatidylinositol 3-kinase p110d isoform, in patients with relapsed or refractory hematologic malignancies. J. Clin. Oncol. 28, Abstract 3032 (2010).
59. Akinleye A, Chen Y, Mukhi N et al. Ibrutinib and novel BTK inhibitors in clinical development. J. Hematol. Oncol. 14, 59 (2013).
60. Dasmahapatra G, Patel H, Dent P et al. Bruton tyrosine kinase (BTK) inhibitor PCI-32765 sinergistically increases proteasome inhibitor activity in diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or reesistant to botrezomib. Br. J. Haematol. 16(1)43-56 (2013).
61. Novero A, Ravella PM, Chen Y et al. Ibrutinib for B cell malignancies. Exp. Hematol. Oncol. 14(1), 4 (2014).
62. Advani RH, Buggy JJ, Sharman JP et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J. Clin. Oncol. 14(1), 88-94 (2013).
63. Ma S, Rosen ST. Enzastaurin. Curr. Opin. Oncol. 19(6), 590-595 (2007).
64. Graff JR, McNulty AM, Hanna KR et al. The protein kinase C beta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res. 65(16), 7462-7469 (2005).
65. Robertson MJ, Kahl BS, Vose JM et al. Phase 2 study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J. Clin. Oncol. 25(13), 1741-1746 (2007).
66. Benjamin D, Colombi M, Moroni C, Hall MN. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat. Rev. Drug Discov. 10(11), 868-880 (2011).
67. Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J. Antibiot. 28(10), 727-732 (1975).
68. Vu C, Fruman DA. Target of rapamycin signaling in leukemia and lymphoma. Clin. Cancer Res. 16(22), 5374-5380 (2010).
69. Witzig TE, Habermann TM, Reeder C et al. A Phase II trial of the oral mtor inhibitor everolimus in relapsed non-Hodgkin's lymphoma and Hodgkin disease. Haematologia 94(2), 436 (2009).
70. Witzens-Harig M, Memmer ML, Dreyling M et al. A Phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor temsirolimus added to standard therapy of rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma-the STORM trial. BMC Cancer 13, 308 (2013).
71. Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood 90(8), 3167-3172 (1997).
72. Stopeck AT, Unger JM, Rimsza LM et al. A Phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108. Leuk. Lymphoma 50(5), 728-735 (2009).
73. Ganjoo KN, An CS, Robertson MJ et al. Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. Leuk. Lymphoma 47(6), 998-1005 (2006).
74. Stopeck AT, Unger JM, Rimsza LM et al. Phase II tiral of standard dose cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab plus bevacizumab for advanced stage diffuse large B-cell lymphoma: SWOG study S0515. Blood 120(8), 1210-1218 (2012).
75. Majchrzak A, Wtkowska M, Medra A et al. Dzialanie cytotoksyczne onkonazy w skojarzeniu z lekami schematu R-CHOP na linii chloniaka rozlanego z duzych komorek B (DLBCL). Postepy. Hig. Med. Dosw. 67, 1166-1172 (2013).